Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ther Drug Monit. 2011 Dec;33(6):673-80. doi: 10.1097/FTD.0b013e318235a5df.
The aim of this study was to develop and validate limited sampling strategies for accurately predicting 12-hour area under the concentration-time curve (AUC(0-12 h)) to provide a practical method for more precise therapeutic drug monitoring of cyclosporine A in stem cell transplant patients. Steady-state cyclosporine blood concentrations were measured within a dosing interval (12 hours post administration) in 35 allogeneic bone marrow transplant patients receiving 238 mg (±117 mg) twice-daily dose of cyclosporine. Limited sampling strategies were developed by multiple linear regression analysis of relationship between cyclosporine A full AUC(0-12 h) values and different combinations of preselected blood concentrations. Validation of the estimating equations was done by a bootstrap-like cross-validation method. Cross-validation results showed that cyclosporine AUC(0-12 h) could be estimated using either 2 or 3 samples within the first 4 hours after drug administration with good accuracy and precision (absolute prediction error of less than 6.2%). The number of estimated area under the drug concentration-time curves within 15% of observed values was greater than 26 (74%) for models used predose concentration with either c(2h) and c(4h) or both. Most of the previously reported single-sample models showed a systematic error in predicting AUC(0-12 h). Although a statistically significant difference in precision of prediction was seen between 3-sample model using c(0), c(2h), and c(4h) and 2-sample models (c(0), c(2h) or c(0), and c(4h)), such a difference (2%) could not be of clinical importance. Other 2-sample estimating equations (models using c(2h) with either c(6h) or c(10h)) with the same degree of precision appear to be less feasible clinically. Cyclosporine AUC(0-12 h) in bone marrow transplant patients could be estimated using 2 or 3 samples within the first 4 hours after drug administration with good accuracy and precision.
本研究旨在开发并验证有限采样策略,以准确预测环孢素 A 的 12 小时 AUC(0-12 h),为干细胞移植患者的环孢素 A 更精确的治疗药物监测提供实用方法。在 35 例接受 238mg(±117mg)每日 2 次剂量的异基因骨髓移植患者中,在给药间隔内(给药后 12 小时)测量稳态环孢素血药浓度。通过多元线性回归分析环孢素 A 全 AUC(0-12 h)值与预选血药浓度的不同组合之间的关系,开发了有限采样策略。通过自举交叉验证方法验证估算方程的验证。交叉验证结果表明,在给药后前 4 小时内,使用 2 或 3 个样本可以很好地准确和精确地估计环孢素 AUC(0-12 h)(绝对预测误差小于 6.2%)。对于使用预给药时的 c(2h)和 c(4h)或两者的模型,估计的药物浓度-时间曲线下面积在观察值的 15%以内的数量大于 26(74%)。大多数先前报道的单样本模型在预测 AUC(0-12 h)时存在系统误差。虽然使用 c(0)、c(2h)和 c(4h)的 3 样本模型与 2 样本模型(c(0)、c(2h)或 c(0)和 c(4h))之间的预测精度存在统计学差异,但这种差异(2%)可能没有临床意义。其他具有相同精度的 2 样本估算方程(使用 c(2h)的模型,分别与 c(6h)或 c(10h)一起使用)在临床上似乎不太可行。在骨髓移植患者中,使用给药后前 4 小时内的 2 或 3 个样本,可以很好地准确和精确地估计环孢素 AUC(0-12 h)。